Data showing that IdeS can silence memory B-cells published in Journal of Immunology

Hansa Medical AB (publ) today announced that results on IdeS effect on B-cells
have been published in Journal of Immunology
The scientific article entitled “The bacterial enzyme IdeS cleaves the IgG-type
of B-cell receptor, abolishes BCR-mediated cell signaling and inhibits memory B
-cell activation”, by Sofia Järnum, Robert Bockermann, Anna Runström, Lena
Winstedt and Christian Kjellman, shows that IdeS not only inactivates plasma IgG
but also cleaves IgG present on B-cells.

Activation via the B-cell receptor on memory cells is a critical step in the
development of antibody producing cells. The now published data show that IdeS
cleaves the IgG-type of B-cell receptor present on human memory B-cells. The
IdeS-treated cells are temporarily silenced and prevented from developing into
antibody producing cells. Furthermore, the data show that IdeS cleaves the B
-cell receptor in vivo in humans.

“The data are conceptually very interesting and we are very pleased that our
work has been accepted in this well renowned scientific journal”, commented
Hansa Medical’s CSO Christian Kjellman.

The data suggest that IdeS treatment could have therapeutic benefits not only
through the degradation of plasma IgG, but it might also delay or mute the
activation of memory cells. IdeS is currently being developed for the removal of
donor specific antibodies in highly sensitized patients on the waiting list for
kidney transplantation. In transplantation, a delay in the activation of memory
B-cells and production of IgG could help the organ to accommodate in its new
host. Furthermore, the concept indicates therapeutic possibilities not only in
transplantation but also in other situations where a memory B-cell response must
be prevented or delayed.

(See full article in Journal of Immunology at
http://m.jimmunol.org/content/early/2015/11/07/jimmunol.1501929)

The information in this press release is disclosed pursuant to the Securities
Markets Act or the Financial Instruments Trading Act. The information was
released for public disclosure on November 10, 2015, at 08.00 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-390 85 30
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About IdeS
IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that
cleaves human IgG antibodies. IdeS aims to degrade immunoglobulin G (IgG) and
has been tested for safety and efficacy in numerous in vitro and in vivo models.
During 2013, a Phase I clinical trial on 29 healthy subjects was conducted,
demonstrating IdeS as efficacious and well tolerated with a favourable safety
profile. During 2014, a Phase II study in 8 sensitized patients awaiting kidney
transplantation was conducted. Preliminary data show that IdeS is effective in
reducing anti-HLA antibody levels in highly sensitized patients on the kidney
transplant waitlist. The study shows that IdeS has the capacity to make
sensitized patients eligible for transplantation by decreasing HLA antibodies to
levels acceptable for transplantation. In addition to transplantation, IdeS has
potential applications in a variety of rare autoimmune diseases. IdeS is
protected by several patents and results of studies with IdeS have been
published in a number of peer reviewed medical and scientific journals.

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory
enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical
development, with potential use in transplantation and rare autoimmune diseases.
Other projects include HBP (a market introduced diagnostic marker for severe
sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical
development). The company is based in Lund, Sweden. Hansa Medical's share
(HMED) is listed on First North Premier in Stockholm with Remium Nordic AB as
Certified Adviser.